Moisture-activated PENTASA delivers effective 5-ASA therapy

PENTASA delivers trusted efficacy

  • PENTASA is the first 5-ASA indicated for the induction of remission in mild to moderate UC.
  • PENTASA has an established efficacy profile.9

PENTASA provides UC patients with significant
treatment benefit9*

  • More than 8 out of 10 patients experienced treatment benefit with PENTASA 4 grams/day in a large placebo-controlled trial.†9

PENTASA provides proven and trusted 5-ASA therapy

  • PENTASA has been delivering the proven efficacy of 5-ASA therapy with a well-established safety profile since 1993.

*Treatment benefit was defined as any improvement of symptoms at endpoint over baseline.9

†Clinical symptoms measured included stool consistency, rectal bleeding, abdominal/rectal pain, and urgency, along with the number of trips to the toilet. Efficacy was assessed using mean change from baseline to endpoint.9

‡At 20 study sites, patients were randomized to receive either placebo or mesalamine (1, 2, or 4 grams/day) for 8 weeks. Efficacy was assessed using the PGA.9

Next: Quality of Life

Demonstrated treatment benefit* in a double-blind, multicenter study (‡9)

Important Safety Information

  • PENTASA is indicated for the induction of remission and for the treatment of patients with mildly to moderately active ulcerative colitis.
  • PENTASA is generally well tolerated. In worldwide clinical trials (N>2100), the most common adverse events were diarrhea (3.4%), headache (2.0%), nausea (1.8%), abdominal pain (1.7%), dyspepsia (1.6%), vomiting (1.5%), and rash (1.0%). As with other mesalamine products, serious adverse events may occur. PENTASA is contraindicated in patients with a hypersensitivity to salicylates. Caution should be used in patients with impaired hepatic or renal function. Patients with pre-existing renal disease, increased BUN or serum creatinine, or proteinuria should be monitored during PENTASA therapy.